The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children

The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children: Multicenter Retrospective Study on 151 Children Over Three Months Old

Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences.

The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus

Inclusion Criteria:

• Minor patient aged 3 months to 17 years
• 2nd line treatment with LEVETIRACETAM or PHENYTOIN after failure of benzodiazepines
• Supported in one of the participating centers during the period from November 1, 2019 to May 31, 2023
• Subject or parents who have not expressed, after information, their opposition to the reuse of their data for the purposes of this research.

Exclusion Criteria:

• Patient or parents having expressed their opposition to participating in the study.